Published in
American Society of Hematology, Blood, p. blood-2017-01-765057
DOI: 10.1182/blood-2017-01-765057
Links
Tools
Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial
Journal article published in 2017 by
Madita Uffmann,
Mareike Rasche 
,
Martin Zimmermann,
Christine von Neuhoff,
Ursula Creutzig,
Michael Dworzak,
Lenie Scheffers,
Henrik Hasle,
C. Michel Zwaan,
Dirk Reinhardt,
Jan-Henning Klusmann
,
Martin Zimmermann,
Christine von Neuhoff,
Ursula Creutzig,
Michael Dworzak,
Lenie Scheffers,
Henrik Hasle,
C. Michel Zwaan,
Dirk Reinhardt,
Jan-Henning Klusmann
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Reducing therapy intensity in the ML-DS 2006 trial did not impair the excellent prognosis in ML-DS compared with the historical control. Early treatment response and gain of chromosome 8 are independent prognostic factors.